Ali Sadoughi
<p>Dr. Ali Sadoughi is Director of Interventional Pulmonology and Bronchoscopy. His clinical expertise is in interventional pulmonology and thoracic oncology, an evolving sub-specialty of pulmonary and critical care medicine. This field focuses on patients with benign and malignant chest diseases.</p>
<p>Dr. Sadoughi performs advanced diagnostic and therapeutic procedures for patients with lung nodules/masses, intra-thoracic lymphadenopathy, pleural diseases, and severe asthma. These include:</p>
<ul>
<li>Sampling of pulmonary lesions; both peripherally and centrally located in the lung; using endobronchial ultrasound (EBUS, both radial and linear array probes) and navigational bronchoscopy</li>
<li>Therapeutic rigid and flexible bronchoscopy on patients with major airway disorders, including tumor de-bulking, airway dilatation and stent placement</li>
<li>Diagnostic and therapeutic procedures on patients with pleural disease and effusion</li>
<li>Therapeutic interventions such as pleurodesis, tunneled pleural catheter and chest tube placement</li>
<li>Bronchial thermoplasty for severe asthma </li>
<li>Endobronchial valve placement for persistent air leak from the lung</li>
</ul>
<p>His other experience is in ultrasonography and echocardiography and their applications in pulmonary and critical care medicine.</p>
<p>Dr. Sadoughi's research interests are in evolution and application of sophisticated and modern technologies for early and minimally invasive diagnosis and treatment of different pulmonary diseases, from lung cancers, to airway disorders, pulmonary hypertension, interstitial lung disease, respiratory failure, and pleural diseases. The outcome of his research studies in pulmonary hypertension and interventional pulmonology has been published in high-ranking medical journals and presented in different national conferences.</p>
<h3>Clinical Specialties</h3>
<ul>
<li>Pulmonary Medicine
<ul>
<li>Interventional Pulmonology</li>
<li>Lung Cancer</li>
</ul>
</li>
<li>Critical Care</li>
</ul>
<h3>Board Certification</h3>
<ul>
<li>Pulmonary Disease</li>
<li>Critical Care Medicine</li>
<li>Internal Medicine</li>
</ul>
<h3>Education & Training</h3>
<ul>
<li>Medical School: Shahid Beheshti University of Medical Sciences</li>
<li>Residency: Kingsbrook Jewish Medical Center</li>
<li>Fellowship: Hofstra-North Shore LIJ School of Medicine</li>
<li>Fellowship: Washington University in Saint Louis</li>
</ul>
<h3>Professional Memberships</h3>
<ul>
<li>American Association of Bronchology and Interventional Pulmonology (AABIP), Member</li>
<li>American College of Chest Physicians (ACCP), Member</li>
<li>American Thoracic Society (ATS), Member</li>
<li>International Association for the Study of Lung Cancer (IASLC), Member</li>
</ul>
Dr. Sadoughi specializes in interventional pulmonology, a subspecialty of pulmonary and critical care medicine that uses endoscopy and other minimally invasive tools to diagnose and treat patients with benign and malignant chest diseases.
<ol>
<li>Bronchomediastinal Fistula From Erosion of Surgical Pledgets Into the Airway, Sadoughi A, Meyers B, Chenna P, Chest. 2015;148:838A. doi:10.1378/chest.2261266</li>
<li>Obstruction of the Trachea with Necrotic Tissue from a Pleomorphic Lung Carcinoma, Sadoughi A, Hyman K, Patel D, Chest. 2014;146:768A. doi:10.1378/chest.1991851.</li>
<li>Diagnosis and Safe Ablation of Endobronchial Hamartoma with Interventional Bronchoscopy, Sadoughi A, Folch E, Majid A. Am J Respir Crit Care Med 189;2014:A4447.</li>
<li>Macrophage migration inhibitory factor mediates hypoxia- induced pulmonary hypertension, Yinzhong Zhang, Arunabh Talwar, Donna Tsang, Annette Bruchfeld, Ali Sadoughi, Maowen Hu, Kennedy Omonuwa, Kai Fan Cheng, Yousef Al-Abed, and Edmund J. Miller, Molecular Medicine, Nov 2011, PMID: 22113497.</li>
<li>Impaired Heart Rate Recovery After Cardio Pulmonary Exercise Testing [CPET] In Patients with Pulmonary Arterial Hypertension, Arunabh Talwar MD, Ali Sadoughi MD, Purvesh Patel MD, Tara George, Donna Tsang, Nina Kohn MS; Chest. 2011;140(4_MeetingAbstracts):723A. doi:10.1378/chest.1119783</li>
<li>A 77-year-old woman with dyspnea and Reynaud phenomenon. Wang J, Sadoughi A, Dedopoulos S, Talwar A, Chest. 2011 Apr;139(4):958-6. PMID: 21467065</li>
<li>Intracranial Pressure Treatment Tailored to Transcranial Doppler-Derived Compliance and Perfusion. Kapinos G, Sadoughi A, Narayan R, oral presentation, November 2013 at the 15th International Conference on Intracranial Pressure and Brain Monitoring, Singapore.</li>
<li>Management of Increased Intracranial Pressure. Sadoughi A, Rybinnik I, Cohen R. The Open Critical Care Medicine Journal, 2013, 6, (Suppl 1: M4) 56-65.</li>
<li>Use of Selective Serotonin Reuptake Inhibitors and Outcomes in Pulmonary Arterial Hypertension, Sadoughi A, Roberts K, Preston I, Lai GP, Mcollister D, Farber HW, Hill NS, Chest. 2013 Apr 4. PMID: 23558791.</li>
<li>Inflammatory Mechanisms in Pulmonary Hypertension, A Sadoughi, Y Zhang, EJ Miller, A Talwar; <em>CML (Current Medical Literature) – Pulmonary Hypertension </em>2010;1(4):93–106.</li>
<li>Computed Tomography Angiogram of the Chest as a Valuable Predicting Tool for Pulmonary Arterial Hypertension, A Sadoughi, N Patel, J Wang, N Kohn, R Shah, A Talwar; Chest. 2010;138(4_MeetingAbstracts):357A. doi:10.1378/chest.10559</li>
<li>Arterial Concentration of Macrophage Migration Inhibitory Factor (MIF) increases with exercise in patients with pulmonary Hypertension (PH), A Sadoughi, EJ Miller, A Talwar, presented at FOCIS 2011, Washington, DC.</li>
<li>Utility of Pulmonary Artery Diameter in Computed Tomography of Chest as a screening tool for Pulmonary Arterial Hypertension, A Sadoughi, T Chandak, N Kohn, R Shah, A Talwar, Presented in ATS Meeting, May 2010.</li>
<li>Relationship of Pulmonary Arterial Oxygen Saturation with Right Atrial Pressure in Pulmonary Hypertension, T Chandak, A Sadoughi, N Kohn, A Talwar, Presented in ATS Meeting, May 2010.</li>
<li>A case of Portopulmonary Hypertension, Sadoughi A, Mukherji R, Mehra S, Talwar A, The Journal of Respiratory Diseases, September, 2008.</li>
<li>Arteriotomy Closure Device Application Following Percutaneous Coronary Intervention May Prevent Bleeding Complication in Patients with Acute Myocardial Infarction, F. Ikeno, M. Ali Sadoughi, J. Lyons, F. Raissi, K. Pourdehmobed, V. Hashemi, S. Emami, H. Kaneda, A. C. Yeung, M. Rezaee, International J. of Cardiology, April 2007, 117(1), 131-132, PMID:16935367.</li>
<li>The Conversion in Application of Percutaneous Coronary Intervention Following the Introduction of Drug Eluting Stents, F. Ikeno, F. Raissi, M. Ali Sadoughi, J.K. Lyons, K. Pourdehmobed, V. Hashemi, S. Emami, H. Kanada, A.C. Yeung, M. Rezaee, International Journal of Cardiology, November 2006, 113(2), 279-280, PMID: 16318883.</li>
<li>Drug-eluting stents alter referral patterns for revascularization in patients with multivessel coronary artery disease, HMO Farouque, Fearon WF, Wu BM, Luna J, Shabari FR, Sadoughi MA, Lee DP, Yeung AC, Heart, Lung, Circulation 2005; 14 Suppl 1: S77, Australia</li>
<li>Changes in the Practice of Percutaneous Coronary Intervention Following the Introduction of Drug Eluting Stents, Raissi F., Sadoughi M.A., Hashemi V., Pourdehmobed K., Farouque O., Lyons J., Emami S., Ikeno F., Kaneda H., Yeung A.C., Rezaee M., TCT (Transcatheter Cardiovascular Therapeutics) meeting 2004, Washington DC, Poster Presentation, 09 / 2004.</li>
</ol>
<p>Ali Sadoughi, MD, is Director, Interventional Pulmonology and Bronchoscopy and Associate Professor, Medicine at Montefiore Einstein. He specializes in interventional pulmonology, a subspecialty of pulmonary and critical care medicine that uses endoscopy and other minimally invasive tools to diagnose and treat patients with benign and malignant chest diseases.</p><p>After earning his Doctor of Medicine at Shahid Beheshti University of Medical Sciences in Tehran, Iran, Dr. Sadoughi completed an internal medicine residency at Kingsbrook Jewish Medical Center. Following this, he completed a pulmonary and critical care fellowship at Hofstra-North Shore LIJ School of Medicine in 2014 and an interventional pulmonary fellowship at Washington University in 2015.</p><p>Dr. Sadoughi's research interests are in developing and applying advanced technologies for early and minimally invasive diagnosis and treatment of pulmonary diseases. These include lung cancers, airway disorders, pulmonary hypertension, interstitial lung disease, respiratory failure and pleural diseases. His work has been published in journals including <em>Chest</em> and the <em>Journal of Molecular Medicine</em>, and he has made presentations at national and international medical meetings. One of his recent research studies focuses on the development of brachytherapy seeds (DaRT) using alpha radiation for the treatment of lung cancer, sponsored by Alpha Tau Ltd. In another study, he works with an international group of pulmonologists on the role of confocal laser endomicroscopy (CLE) in the diagnosis of different benign and malignant lung diseases. His work related to increased precision and accuracy of biopsy of peripheral lung nodules by intraprocedural 3D scanning in combination with ultrathin bronchoscopy has been published in the <em>Journal of Bronchology and Interventional Pulmonology</em>. Another area of Dr. Sadoughi’s research involves the synergy of local therapies such as cryotherapy with immunotherapy in the treatment of lung cancer. He has presented this exciting topic at the American Association of Bronchology and Interventional Pulmonology (AABIP) Conference in 2022.</p><p>Dr. Sadoughi is board certified in interventional pulmonology, pulmonary disease, critical care medicine and internal medicine. He is a member of professional societies such as the American Association of Bronchology and Interventional Pulmonology, the World Association of Bronchology and Interventional Pulmonology, the American College of Chest Physicians, the American Thoracic Society and the International Association for the Study of Lung Cancer. He has contributed his research to the U.S. News, Politico New York and OncLive, and has been an editorial member and reviewer of multiple medical journals.</p>
Norman L. Rosen
Divya B. Reddy
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman'; background-color: #fefefe;"><strong><span style="font-size: 12pt; font-family: Calibri;">Education:</span></strong></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman'; background-color: #fefefe;"><span style="font-size: 12pt; font-family: Calibri;">Dr. Reddy earned her medical degree from Padmashree Dr. D. Y. Patil Medical College, India. She completed a master's degree in clinical epidemiology from Boston University School of Public Health prior to starting her Internal Medicine Residency training at Boston University Medical Center. Her post-graduate training also included a Fellowship in Pulmonary and Critical Care Medicine from Boston University Medical Center with a particular focus on pulmonary infections and associated lung destruction. </span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman'; background-color: #fefefe;"><strong><span style="font-size: 12pt; font-family: Calibri;">Research Interests:</span></strong></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman'; background-color: #fefefe;"><span style="font-size: 12pt; font-family: Calibri;">Dr. Reddy has been involved in several patient-oriented research projects in pulmonary infections. As an investigator in the Regional Prospective Observational Research in Tuberculosis (RePORT) cohort in Puducherry and Tamil Nadu, India her work focused on the impact of smoking and biomass fuel use on TB Disease and its treatment outcomes. She is currently developing a database of patients with non-tuberculous mycobacterial infections seen at Montefiore Medical Center in collaboration with the Division of Infectious Diseases. The goal of this project is to better characterize the natural history and clinical outcomes of these infections. She is also involved in the Women’s Interagency HIV Study (WIHS) as the Bronx site pulmonologist and co-investigator to assess the impact of HIV on the development of chronic lung diseases.</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman'; background-color: #fefefe;"><span style="font-size: 12pt; font-family: Calibri;"><strong>Clinical Interests:</strong></span></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria;"><span style="font-family: Calibri; background-color: #fefefe;">1. Bronchiectasis </span></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria;"><span style="font-family: Calibri; background-color: #fefefe;">2. Tuberculosis</span></p>
<p class="MsoNormal" style="margin: 0in -67.5pt 0.0001pt 0in; font-size: medium; font-family: Cambria;"><span style="font-family: Calibri; background-color: #fefefe;">3. Nontuberculous Mycobacterial (NTM) Infections </span></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria;"><span style="font-family: Calibri; background-color: #fefefe;">4. Obstructive lung diseases </span></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria;"><span style="font-family: Calibri; background-color: #fefefe;">5. COVID-19</span></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria;"> </p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman'; background-color: #fefefe;"><strong><span style="font-size: 12pt; font-family: Calibri;">Board Certification:</span></strong></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman'; background-color: #fefefe;"><span style="font-size: 12pt; font-family: Calibri;">Dr. Reddy is board-certified in Internal Medicine, Pulmonary and Critical Care Medicine and is a<span class="apple-converted-space"> </span><span style="border: 1pt none windowtext; padding: 0in;">member of numerous professional societies, including the American Thoracic Society and the Society of Critical Care Medicine.</span></span></p>
Bronchiectasis, Nontuberculous Mycobacterial infections, COPD, Asthma, Interstitial Lung Disease<quillbot-extension-portal></quillbot-extension-portal><quillbot-extension-portal></quillbot-extension-portal>
Bronchiectasis, Nontuberculous mycobacterial infections.<quillbot-extension-portal></quillbot-extension-portal>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria; text-align: justify; text-indent: 4.5pt;"><strong><span style="font-family: Calibri;">Original Publications:</span></strong></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria; text-align: justify; text-indent: 4.5pt;"><span style="font-family: Calibri;"> </span></p>
<p class="MsoNormalCxSpMiddle" style="margin: 0in -0.25in 0.0001pt 27pt; text-indent: -22.5pt;"><span style="font-family: Calibri;">1. <strong>Reddy D</strong>, Little F; Glucocorticoid-Resistant Asthma: More than meets the eye; <em>J Asthma</em> December 2013, Vol. 50, No. 10, Pages 1036-1044, PMID 23923995</span></p>
<p class="MsoNormalCxSpMiddle" style="margin: 0in -0.25in 0.0001pt 27pt; text-indent: -22.5pt;"><span style="font-family: Calibri;">2. <strong>Reddy D</strong>, O’Donnell MR, Welter-Frost AM, Coe A, Horsburgh CR. Discordance between Tuberculin Skin Test and Interferon Gamma Release Assay is Associated with Previous Latent Tuberculosis Infection Treatment. <em>Mycobact Dis</em> 2016, 6:227. doi: 10.4172/2161-1068.1000227.</span></p>
<p class="MsoNormalCxSpMiddle" style="margin: 0in -0.25in 0.0001pt 27pt; text-indent: -22.5pt;"><span style="font-family: Calibri;">3. <strong>Divya Reddy</strong>, Jacob Walker, Gary Brandeis MD, Matt Russell MD, C Robert Horsburgh Jr, Natasha Hochberg; Latent Tuberculosis Infection Screening Practices in Long-Term Care Facilities<em>; J Am Geriatr Soc</em>, 2017, 65: 1145–1151. doi:10.1111/jgs.14696, PMID 28467605</span></p>
<p class="MsoNormalCxSpMiddle" style="margin: 0in -0.25in 0.0001pt 27pt; text-indent: -22.5pt;"><span style="font-family: Calibri;">4. </span><strong style="font-family: Cambria; font-size: 12pt;"><span style="font-family: Calibri;">Divya Reddy</span></strong><span style="font-size: 12pt; font-family: Calibri;">, Yicheng Ma, Subitha Lakshminarayanan, Swaroop Sahu, Laura F. White, Ayiraveetil Reshma, Gautam Roy, Padmini Salgame, Selby Knudsen, Jerrold J. Ellner, C. Robert Horsburgh, Jr., Sonali Sarkar, Natasha S. Hochberg, Severe Undernutrition in Children Affects Tuberculin Skin Test Performance in Southern India. <em>PLoS ONE 16(7): e0250304. https://doi.org/10.1371/journal. pone.0250304, </em></span><span style="font-size: 12pt; font-family: Calibri;">PMID 34270546</span></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: Cambria;"> </p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: Cambria;"> </p>
<p class="MsoNormal" style="margin: 0in -0.25in 0.0001pt 40.5pt; font-size: medium; font-family: Cambria; text-indent: 4.5pt;"><span style="font-family: Calibri;"> </span></p>
<p class="MsoNormal" style="margin: 0in -0.25in 0.0001pt 40.5pt; font-size: medium; font-family: Cambria; text-indent: -0.5in;"><strong><span style="font-family: Calibri;">Book Chapters:</span></strong></p>
<p class="MsoNormal" style="margin: 0in -0.25in 0.0001pt 40.5pt; font-size: medium; font-family: Cambria; text-indent: 4.5pt;"><span style="font-family: Calibri;"> </span></p>
<p class="MsoNormalCxSpMiddle" style="margin: 0in -0.25in 0.0001pt 27pt; text-indent: -22.5pt;"><span style="font-family: Calibri;">1. O’Donnell M, <strong>Reddy D</strong>, Saukkonen J; Antimycobacterial agents; 19<sup>th</sup> Edition of <em>Harrison’s Principles of Internal Medicine</em>, McGraw-Hill Professional, 2015. Volume 2. Chapter 205e, p. 1132-41</span></p>
<p class="MsoNormalCxSpMiddle" style="margin: 0in -0.25in 0.0001pt 27pt; text-indent: -22.5pt;"><span style="font-family: Calibri;">2. <strong>Reddy D</strong>, O’Donnell M; Antimycobacterial agents; 20<sup>th</sup> Edition of <em>Harrison’s Principles of Internal Medicine, </em>McGraw-Hill Professional, 2018. Volume 1. Chapter 176, p. 1270-79</span></p>
<p class="MsoNormalCxSpMiddle" style="margin: 0in -0.25in 0.0001pt 27pt; text-indent: -22.5pt;"><span style="font-family: Calibri;">3. <strong>Reddy D</strong>, Saukkonen J; Hepatoxicity associated with anti-tuberculosis treatment;<strong> </strong>3<sup>rd</sup> Edition of <em>Textbook of</em> <em>Tuberculosis and Nontuberculous Mycobacterial Diseases,</em> Jaypee Brothers Medical Publishers, 2019. Chapter 45, p. 637-643</span></p>
<p class="MsoNormalCxSpMiddle" style="margin: 0in -0.25in 0.0001pt 27pt; text-indent: -22.5pt;"><span style="font-family: Calibri;">4. <strong>Divya Reddy</strong>, Jerrold Ellner; Pathogenesis of Tuberculosis; 6<sup>th </sup>Edition of <em>Clinical Tuberculosis</em>, CRC Press, 2020. Chapter 4, p. 51-76</span></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria;"><span style="font-family: Calibri;"> </span></p>
<p>Divya Reddy, MD, MPH, is Program Director, Pulmonary and Critical Care Fellowship and Associate Professor, Medicine at Montefiore Einstein. Her clinical focus centers on bronchiectasis, nontuberculous mycobacterial infections, chronic obstructive pulmonary disease (COPD), asthma and interstitial lung disease.</p><p>After earning her Bachelor of Medicine, Bachelor of Surgery at Dr. D.Y. Patil Medical College in Mumbai, India in 2006, Dr. Reddy moved to the United States to continue her medical training, earning her Master of Public Health at Boston University in 2008. She remained there to complete her internal medicine internship in 2009, followed by her internal medicine residency in 2011. Dr. Reddy then completed a pulmonary and critical care fellowship at Boston University in 2014.</p><p>Building on her clinical experience, Dr. Reddy’s research is focused on bronchiectasis and nontuberculous mycobacterial infections. She has been principal investigator and co-investigator on several funded research projects, and her work has been published in numerous peer-reviewed journals, book chapters, review articles and abstracts. She has also given national and international invited presentations, and is a reviewer for scientific journals including the <em>Journal of American Geriatric Society</em>, <em>Annals of American Thoracic Society</em> and the <em>Journal of Infectious & Non-Infectious Diseases</em>, among others.</p><p>Dr. Reddy is board certified in Pulmonary Medicine and Critical Care Medicine by the American Board of Internal Medicine. She is a member of the American Thoracic Society, the American College of Chest Physicians and the Association of Pulmonary and Critical Care Medicine Program Directors. In 2014 and 2015, Dr. Reddy received the Potts Memorial Foundation Grant award.</p>
Mark A. Ramirez
David J. Prezant
<p>Dr. David Prezant is the Chief Medical Officer at the Office of Medical Affairs for the Fire Department of the City of New York (FDNY). Dr. Prezant directs all medical protocol development for both day-to-day operations and homeland security issues. He is also Co-Director of the FDNY World Trade Center Medical Monitoring Program and the Senior Pulmonary Consultant for FDNY.</p>
<p>Dr. Prezant is a member of the Institute of Medicine's Committee on Personal Protective Equipment in the Workplace, the National Fire Protection Association's Health and Safety Committee, and the International Association of Firefighters Redmond Medical Advisory Board. He is a Professor of Medicine at the Albert Einstein College of Medicine; Director of Albert Einstein Medical School's Pulmonary Course for medical students and the Research Director for their Unified Pulmonary Division.</p>
<p>Dr. Prezant responded on 9/11/01 to the World Trade Center and was present during the collapse and its aftermath. Since that day, he and Dr. Kelly (FDNY's Chief Medical Officer at the Bureau of Health Services) have initiated a multi-million dollar medical monitoring and treatment program for FDNY firefighters funded by FDNY, the Centers for Disease Control and Prevention (CDC) and the National Institute for Occupational Safety and Health (NIOSH).</p>
<p>Dr. Prezant is the Principal Investigator for the FDNY Data Coordinating Center for the WTC Medical Monitoring Program and is on the Steering Committee for the WTC Medical Monitoring Program. He served as a member of the EPA WTC Technical Advisory Committee, the NYC Dept of Health WTC Registry Scientific Advisory Board, the NYS Governor's WTC panel and the NYC Mayor's medical advisory board.</p>
<p>Dr. Prezant has written extensively on pulmonary physiology, firefighter health and safety and since 9/11 on the health impact of World Trade Center Collapse on NYC Firefighters and EMS rescue workers. His group was the first to describe WTC Cough Syndrome (New England Journal of Medicine 2002) and has published extensively on this subject in the CDC MMWR, American Journal of Respiratory and Critical Care Medicine, Chest and Environmental Health Perspectives.</p>
<p>His major research interest is in determining the mechanisms responsible for accelerated decline in longitudinal pulmonary function and/or airway hyperreactivity in firefighters after WTC exposure. Other interests are in determining the mechanisms responsible for the increased incidence of sarcoidosis in firefighters after WTC exposure.</p>
<p><strong>Clinical Specialty Areas</strong></p>
<ul>
<li>environmental and occupational lung disease</li>
<li>firefighters respiratory disease</li>
<li>disaster medicine</li>
<li>pulmonary embolism</li>
<li>general pulmonary medicine</li>
</ul>
<p><strong>More</strong></p>
<p><a href="/medicine/pulmonarymedicine/pulmonary_about.aspx?id=14538">Seven Years Later, a Cough and a Covenant</a> (September 10, 2008)</p>
<ol>
<li>World Trade Center site. N Eng J Med 2002;347:806-15.</li>
<li>Banauch GI, McLaughlin M, Hirschhorn R, Corrigan M, Kelly KJ, Prezant DJ. Injuries and Illnesses among New York City Fire Department rescue workers after responding to the World Trade Center Attacks. MMWR 2002;51:1-5.</li>
<li>Prezant DJ, Kelly KJ, Jackson B, Peterson D, Feldman D, Baron S, Mueller CA, Bernard B, Lushniak B, Smith L, BerryAnn R, Hoffman B. Use of respiratory protection among responders at the World Trade Center Site, New York City, September 2001. MMWR 2002;51:6-8.</li>
<li>Rom WN, Weiden M, Garcia R, Ting AY, Vathesatogkit P, Tse DB, McGuinness G, Roggli V, Prezant DJ. Acute eosinophilic pneumonia in a New York City firefighter exposed to world trade center dust. Am. J. Resp. Crit. Care Med. 2002;166:797-800.</li>
<li>Banauch GI, Alleyne D, Sanchez R, Olender K, Weiden M, Kelly KJ, and PREZANT DJ. Persistent bronchial hyperreactivity in New York City firefighters and rescue workers following collapse of World Trade Center. Am. J. Resp. Crit. Care Med. 2003; 168:54-62.</li>
<li>Edelman P, Osterloh J, Pirkle J, Grainger J, Jones R, Blount B, Calafat A, Turner W, Caudill S, Feldman DM, Baron S, Bernard BP, Lushniak BD, Kelly KJ, PREZANT DJ. Biomonitoring of chemical exposure among New York City firefighters responding to the World Trade Center fire and collapse. Environ Health Perspect, 2003; 111:1906-1911.</li>
<li>Feldman DM, Baron S, Mueller CA, Bernard BP, Lushniak BD, Kelly KJ, PREZANT DJ. Initial symptoms, respiratory function and respirator use in New York City firefighters responding to the World Trade Center (WTC) disaster. Chest 2004;125:1256-64.</li>
<li>World Trade Center dust. Environ Health Perspect, 2004; 112:1564-1569.</li>
<li>Banauch GI, Dhala A, Alleyne D, Alva R, Santhyadka G, Krasko A, Weiden M, Kelly KJ, Prezant DJ. Bronchial hyperreactivity and other inhalation lung injuries in rescue/recovery workers after the World Trade Center collapse. Crit Care Med. 2005;33:S102-S106.</li>
<li>World Trade Center site. Curr Opin Pulm Med 2005; 11:160-8.</li>
<li>Paul Greene, Dianne Kane, Grace Christ, Sallie Lynch and Malachy Corrigan. FDNY crisis counseling: innovative responses to 9/11 firefighters, families, and communities. Published 2005.A textbook in counseling at FDNY after WTC.</li>
<li>Bars MP, Banauch GI, Appel DW, Andreaci M, Mouren P, Kelly KJ, Prezant DJ. Tobacco Free with FDNY: The New York City Fire Department World Trade Center Tobacco Cessation Study. Chest 2006; 129:979-987.</li>
<li>World Trade Center exposure in the New York City Fire Department. Am. J. Respir. Crit. Care Med. 2006; 174:312-319.</li>
<li>Friedman S, Cone J, Eros-Sarnyai M, Prezant D,m Szeinuk J, Clark N, Milek D, Levin S, Gillio R. Clinical guidelines for adults exposed to World Trade Center Disaster (Respiratory and Mental Health). City Health Info (CHI), NYC Department of Health and Mental Hygiene. September 2006</li>
<li>Lioy PJ, Pellizzari E, and Prezant DJ. Understanding and learning from the WTC Aftermath and its affect on health through Human Exposure Science. Environ. Science Technology. November 15, 2006 ; 6876-6885.</li>
<li>Izbicki G, Chavko R, Banauch GI, Weiden M, Berger K, Kelly KJ, Aldrich TK and Prezant DJ. World Trade Center Sarcoid-like Granulomatous Pulmonary Disease in New York City Fire Department Rescue Workers. CHEST (In press)</li>
<li>Izbicki G, Chavko R, Banauch GI, Weiden M, Berger K, Kelly KJ, Hall C, Aldrich TK and Prezant DJ.  World Trade Center Sarcoid-like Granulomatous Pulmonary Disease in New York City Fire Department Rescue Workers.  Chest, 2007;131:1414-1423</li>
<li>Weiden M, Banauch G, Kelly KJ, and Prezant DJ. Environmental and Occupational Medicine. Firefighters Health and Health Effects of the World Trade Center Collapse. Pgs 477-490. 4th Edition, Edited by Rom WN and Markowitz S. Lippincott-Raven Inc. Philadelphia, 2007.</li>
<li>Alvarez J, Rosen C, Davis K, Smith G, Corrigan M. Stay Connected : psychological services for retired firefighters after 11 September 2001.  PreHospital Disaster Med. 2007 ;22 :49-54.</li>
<li>Menendez AM, Molloy J., Magaldi MC. Health responses of New York City firefighter spouses and their families post-September 11, 2001 terrorist attacks.  Issues Ment Health Nurs. 2006; 27:905-17.</li>
<li>Kelly KJ, Niles J, McLaughlin MT, Carrol S, Corrigan M, Al-Othman F, and Prezant DJ.  World Trade Center health Impacts on FDNY Rescue Workers - a six year assessment, September 2001 to 2007.  Fire Department of the City of New York, October 2007. Available on-line at: <a href="http://www.nyc.gov/html/om/pdf/2007/wtc_health_impacts_on_fdny_rescue_w…; target="_blank">http://www.nyc.gov/html/om/pdf/2007/wtc_health_impacts_on_fdny_rescue_w…;
<li>Prezant DJ. WTC Cough Syndrome and its Treatment. Lung. 2008 ; 186 :94S-102S.</li>
<li>Banauch GI, Izbicki G, Chavko R, Christodoulou V, Weiden MD, Webber MP, Cohen HW, Gustave J, Aldrich TK, Kelly KJ, and Prezant DJ. Trial of Prophylactic Inhaled Steroids to Prevent or Reduce Pulmonary Function Decline, Pulmonary Symptoms and Airway Hyperreactivity in Firefighters at the World Trade Center Site. Disaster Medicine and Public Health Preparedness 2008; 2:33-39.</li>
<li>Prezant DJ, Levin S, Kelly KJ, Aldrich TK.  Upper and Lower Respiratory Diseases after Occupational and Environmental Disasters.  Mt. Sinai Medical Journal (In Press).     </li>
</ol>
<p> </p>
Stuart Packer
<p>Stuart Packer, MD, is a medical oncologist with extensive experience in treating lung, head and neck, prostate and other types of cancer. After graduating magna cum laude from Case Western Reserve University, Dr. Packer received his medical degree from the State University of New York/Downstate Medical Center. He went on to complete a residency in medicine and fellowship in hematology/medical oncology at Duke University Medical Center. Since then Dr. Packer has held clinical and teaching positions at leading cancer centers, including Memorial Sloan-Kettering Cancer Center, Mount Sinai School of Medicine and Montefiore Einstein Center for Cancer Care.</p>
<p>Dr. Packer’s clinical expertise is in medical management of lung cancer, head and neck cancer and prostate cancer. He is director of the melanoma and sarcoma programs at Montefiore Einstein Center for Cancer Care. In addition, Dr. Packer is medical director of Montefiore’s Oncology Care Model (OCM), an alternative payment model sponsored by the Centers for Medicare and Medicaid Services and aimed at improving patient care coordination and appropriateness of care.</p>
<p>Dr. Packer is the author or co-author of medical textbook chapter and articles in peer-reviewed journals, including <em>Cancer, Clinical Cancer Research, British Medical Journal</em> and <em>Lung Cancer</em>. He is a member of the American Society of Clinical Oncology and the American Society of Hematology.</p>
Dr. Packer’s clinical expertise is in medical management of lung cancer, head and neck cancer and prostate cancer.
<p>Stuart Packer, MD, is a medical oncologist with extensive experience in treating lung, head and neck, prostate and other types of cancer. After graduating magna cum laude from Case Western Reserve University, Dr. Packer received his medical degree from the State University of New York/Downstate Medical Center. He went on to complete a residency in medicine and fellowship in hematology/medical oncology at Duke University Medical Center. Since then Dr. Packer has held clinical and teaching positions at leading cancer centers, including Memorial Sloan-Kettering Cancer Center, Mount Sinai School of Medicine and Montefiore Einstein Center for Cancer Care.</p><p>Dr. Packer’s clinical expertise is in medical management of lung cancer, head and neck cancer and prostate cancer. He is director of the melanoma and sarcoma programs at Montefiore Einstein Center for Cancer Care. In addition, Dr. Packer is medical director of Montefiore's Oncology Care Model (OCM), an alternative payment model sponsored by the Centers for Medicare and Medicaid Services and aimed at improving patient care coordination and appropriateness of care.</p><p>Dr. Packer is the author or co-author of medical textbook chapter and articles in peer-reviewed journals, including <em>Cancer</em>, <em>Clinical Cancer Research</em>, <em>British Medical Journal</em> and <em>Lung Cancer</em>. He is a member of the American Society of Clinical Oncology and the American Society of Hematology.</p>
Sun Young Oh
<span style="color:#4d4d4d;font-family:Arial, Helvetica, source-code-pro, Menlo, Monaco, Consolas, 'Courier New', monospace;font-size:16px;background-color:#ffffff;">The clinical focus is on medical oncology and the systemic treatment of breast cancer.</span>
<span style="color:#4d4d4d;font-family:Arial, Helvetica, source-code-pro, Menlo, Monaco, Consolas, 'Courier New', monospace;font-size:16px;background-color:#ffffff;">Dr. Oh’s research follows her clinical focus and has been shared through publication in peer-reviewed journals.</span>
<p>Sun Young Oh, MD, is an Oncologist and Assistant Professor, Oncology and Medicine at Montefiore Einstein. Her clinical focus is on medical oncology and the systemic treatment of breast cancer.</p><p>In 2003, Dr. Oh completed her Doctor of Medicine at Ewha Womans University in Seoul, South Korea. She pursued postdoctoral training in the United States completing her internal medicine internship at Lutheran Medical Center in 2006, her internal medicine residency at Jacobi Medical Center/Albert Einstein College of Medicine in 2008 and her hematology and oncology fellowship at Tufts Medical Center/Tufts University School of Medicine in 2015.</p><p>Dr. Oh’s research follows her clinical focus and has been shared through publication in peer-reviewed journals.</p><p>Dr. Oh is board certified in internal medicine, medical oncology and hematology. She is a member of the American Society of Clinical Oncology</p>